Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from LBT Innovations Limited ( (AU:CC5) ).
Clever Culture Systems Ltd has issued 3,545,581 ordinary fully paid shares without disclosure to investors, in compliance with the Corporations Act 2001. This move signifies the company’s ongoing commitment to expanding its operations and strengthening its market position in the AI microbiology automation industry, potentially impacting stakeholders by enhancing its financial resources and operational capabilities.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is a leader in AI microbiology automation, providing intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the company has developed the Automated Plate Assessment System (APAS Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading and is sold to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories for infectious disease diagnostics. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS Independence to clinical customers in the US and selected European countries.
Average Trading Volume: 1,800,100
Technical Sentiment Signal: Hold
Current Market Cap: A$62.84M
For an in-depth examination of CC5 stock, go to TipRanks’ Overview page.